Lilly Asks People Who Took Compounded Tirzepatide for Their Medical Records
Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules
Novo's Wegovy Backed by EU Regulator For Obesity-Related Heart Conditions. FDA Could Be Next. -- Barrons.com
The Price War in Weight-Loss Drugs Is Here -- WSJ
Trump refuses to sell stocks, market turmoil may trigger a new round of selling.
Donald Trump recently stated that he will not sell his stocks in Trump Media & Technology Group (DJT). However, starting from this Thursday, he has the option - an option that has been unavailable since the social media company went public in March.
EU regulatory institutions support the use of novo-nordisk a/s (NVO.US) Wegovy to treat obesity-related heart disease.
Danish pharmaceutical company novo-nordisk a/s (NVO.US) said on Thursday that the european medicines agency (EMA) supports the use of the company's popular drug Wegovy to relieve heart failure in obese patients.
UBS Group: Harris' victory will be bullish for utility bonds, while Trump will boost energy.
The UBS Group credit strategy director said that if Harris wins the election, it will boost bonds in industries such as utilities. Trump, on the other hand, will boost industries such as energy.
Eli Lilly and Co (LLY.US) hopes to ask users of generic drugs to provide medical records. Are they ready to wage war on the "generic version of weight loss drugs"?
Eli Lilly and Company stated that, for safety reasons, they requested this information; some dispensing pharmacies stated that these products are legal and necessary.
Express News | Eli Lilly and Co: We hope that those who have used cheap weight loss drugs will provide records.
Tandem Diabetes Rises as Insulin Pump Cleared for Use in EU With Lilly Insulin
Weight Loss Drug Developer BioAge Seeks up to $602M Valuation in U.S. IPO
Is the Federal Reserve starting an interest rate cut cycle on the cusp of a wave, possibly revealing the outcome of the election in advance?
Taking history as a lesson, in an election year with declining interest rates, the probability of the incumbent president or challenger winning is greater.
Vanda Slips as FDA Rejects Therapy for Stomach Condition
Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
Eli Lilly and Company (LLY): Hedge Funds Are Bullish On This Counter Cyclical and Defensive Stock to Invest In
ResMed Slips as Wolfe Downgrades on GLP-1 Threat From Lilly
Sen. Sanders Says Generic Drugmakers Willing to Sell Ozempic for Less Than $100
Weight Loss Drug Pricing Under Fire With Pills on the Horizon
ResMed Stock Is S&P 500's Worst Performer. GLP-1 Drugs Are a Risk. -- Barrons.com
Over a hundred former Republican officials have written an open letter supporting Harris: Trump is not suitable to regain the White House.
① These Republican officials have served in institutions such as the White House, Department of Defense, Department of the Treasury, Department of State, Department of Justice, Department of Homeland Security, and Congress; ② These officials expressed that although there may be policy differences with Harris, compared to the "chaos and unethical behavior" displayed by Trump, these concerns are insignificant.